Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

noretreat

Rank: Vice President [?]

Points: 1412 [?]

Votes: 14 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

in response to

Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

BearDownAZ

posted on Oct 05, 2020 09:50AM

This adds to Zen-3694 credibility and should make it easier to fund trials. Its still a long road to the promised land, however, at least in my view.

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply